Press Release Contact

Press release:
Sethera Therapeutics’ Polymacrocyclic Peptide Platform Selected for CDMRP-Supported Mutant p53 Breast Cancer Program
August 10, 2026, 12:00 GMT

For questions about this press release, please contact the person or organization listed below.

Karsten Eastman
Sethera Therapeutics, Inc.
+1 8018504367